Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Season 2, Episode 37, Jul 30, 01:30 PM
Share
Subscribe
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Eileen O’Reilly, MD, and Brian Wolpin, MD, MPH, discuss current principles for molecular testing and emerging targeted therapy approaches for patients with metastatic pancreatic ductal adenocarcinoma.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Episode Description
In this podcast, experts Eileen O’Reilly, MD, and Brian Wolpin, MD, MPH, discuss current principles for molecular testing and emerging targeted therapy approaches for patients with metastatic pancreatic ductal adenocarcinoma.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the role of molecular profiling to identify actionable alterations in patients with advanced pancreatic adenocarcinoma (PDAC)
- Analyze clinical data from key trials evaluating emerging therapeutic agents for metastatic PDAC
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Revolution Medicines.
This activity is supported by an educational grant from Revolution Medicines.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 9235
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 9235
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Eileen M. O’Reilly, MD
Professor of Medicine
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers, Gastrointestinal Oncology Service
Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AbbVie, Alligator Bioscience, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tango, Tempus, Vector, Yiviva; Institutional research support: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva.
Faculty:
Brian Wolpin, MD, MPH
Professor of Medicine
Director, Gastrointestinal Cancer Center
Director, Hale Family Center for Pancreatic Cancer Research
Robert T. & Judith B. Hale Chair in Pancreatic Cancer
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consulting/advisory board: Agenus, BeiGene, EcoR1 Capital, Harbinger Health, Ipsen, Mirati/Bristol Myers Squibb (BMS), Revolution Medicines, Tango Therapeutics, Third Rock Ventures; Funding (paid to institution): Agios, Amgen, AstraZeneca, Eli Lilly, Harbinger Health, Novartis, Revolution Medicines.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
Eileen M. O’Reilly, MD
Professor of Medicine
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers, Gastrointestinal Oncology Service
Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AbbVie, Alligator Bioscience, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tango, Tempus, Vector, Yiviva; Institutional research support: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva.
Faculty:
Brian Wolpin, MD, MPH
Professor of Medicine
Director, Gastrointestinal Cancer Center
Director, Hale Family Center for Pancreatic Cancer Research
Robert T. & Judith B. Hale Chair in Pancreatic Cancer
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consulting/advisory board: Agenus, BeiGene, EcoR1 Capital, Harbinger Health, Ipsen, Mirati/Bristol Myers Squibb (BMS), Revolution Medicines, Tango Therapeutics, Third Rock Ventures; Funding (paid to institution): Agios, Amgen, AstraZeneca, Eli Lilly, Harbinger Health, Novartis, Revolution Medicines.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on targeted therapy approaches for metastatic PDAC, go to https://www.gotoper.com/annual-oncology-meeting-25-pdac-activity
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.